Clinical Trial Results:
Efficacy and Safety of B-Domain Deleted Recombinant Porcine Factor VIII (OBI-1) in the Treatment of Acquired Hemophilia A Due to Autoimmune Anti-Factor VIII Inhibitory Antibodies
Summary
|
|
EudraCT number |
2011-000181-34 |
Trial protocol |
GB SE DE HU IT |
Global end of trial date |
09 Oct 2013
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
18 Feb 2016
|
First version publication date |
06 Aug 2015
|
Other versions |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
OBI-1-301
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
NCT01178294 | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
Baxalta Innovations GmbH
|
||
Sponsor organisation address |
Industriestrasse 67, Vienna, Austria, 1221
|
||
Public contact |
Clinical Trial Registries and Results Disclosure, Baxalta Innovations GmbH, ClinicalTrialsDisclosure@baxalta.com
|
||
Scientific contact |
Clinical Trial Registries and Results Disclosure, Baxalta Innovations GmbH, ClinicalTrialsDisclosure@baxalta.com
|
||
Sponsor organisation name |
Baxalta US Inc.
|
||
Sponsor organisation address |
One Baxter Way, Westlake Village, United States, 91362
|
||
Public contact |
Clinical Trial Registries and Results Disclosure, Baxalta US Inc., ClinicalTrialsDisclosure@baxalta.com
|
||
Scientific contact |
Clinical Trial Registries and Results Disclosure, Baxalta US Inc., ClinicalTrialsDisclosure@baxalta.com
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
27 May 2014
|
||
Is this the analysis of the primary completion data? |
Yes
|
||
Primary completion date |
15 Jul 2013
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
09 Oct 2013
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
The primary objective of Studies OBI-1-301 and extended protocol OBI-1-301a were to
evaluate the efficacy of OBI-1 for the treatment of serious bleeding events in subjects
with acquired hemophilia with autoimmune inhibitory antibodies to human factor VIII. The primary efficacy outcome was the proportion of serious bleeding events
responsive to OBI-1 therapy at 24 hours after the initiation of treatment determined using
a well-defined, ordinal scale (effective - partially effective - poorly effective - not effective).
|
||
Protection of trial subjects |
This study was conducted in accordance with the clinical protocol, the
International Conference on Harmonization Guideline for Good Clinical Practice E6
(ICH GCP, April 1996), Title 21 of the US Code of Federal Regulations (US CFR),
the European Clinical Trial Directive (2001/20/EC and 2005/28/EC), and applicable
national and local regulatory requirements.
|
||
Background therapy |
- | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
10 Nov 2010
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
Yes
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Canada: 5
|
||
Country: Number of subjects enrolled |
United States: 16
|
||
Country: Number of subjects enrolled |
United Kingdom: 4
|
||
Country: Number of subjects enrolled |
India: 4
|
||
Worldwide total number of subjects |
29
|
||
EEA total number of subjects |
4
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
10
|
||
From 65 to 84 years |
16
|
||
85 years and over |
3
|
|
|||||||||||||||||||
Recruitment
|
|||||||||||||||||||
Recruitment details |
Enrollment was conducted at 12 clinical sites in 4 countries (USA, Canada, UK, India). Eight sites enrolled subjects under Protocol OBI-1-301 only. Two US sites enrolled subjects under the expanded access protocol OBI-1-301a and subsequently under protocol OBI-1-301. Another 2 US sites enrolled subjects under OBI-1-301a only. | ||||||||||||||||||
Pre-assignment
|
|||||||||||||||||||
Screening details |
- | ||||||||||||||||||
Pre-assignment period milestones
|
|||||||||||||||||||
Number of subjects started |
29 | ||||||||||||||||||
Number of subjects completed |
29 | ||||||||||||||||||
Period 1
|
|||||||||||||||||||
Period 1 title |
Overall trial (overall period)
|
||||||||||||||||||
Is this the baseline period? |
Yes | ||||||||||||||||||
Allocation method |
Not applicable
|
||||||||||||||||||
Blinding used |
Not blinded | ||||||||||||||||||
Arms
|
|||||||||||||||||||
Arm title
|
Treatment of serious bleeding episodes | ||||||||||||||||||
Arm description |
Initial treatment with OBI-1 at dose of 200 U/kg, additional doses at the discretion of the investigator based on FVIII activity level and clinical assessment of response to treatment (upper limit: 400 U/kg every 2 hours) | ||||||||||||||||||
Arm type |
Experimental | ||||||||||||||||||
Investigational medicinal product name |
OBI-1
|
||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||
Other name |
Obizur
|
||||||||||||||||||
Pharmaceutical forms |
Powder and solution for solution for injection
|
||||||||||||||||||
Routes of administration |
Intravenous use
|
||||||||||||||||||
Dosage and administration details |
Initial dose: 200 U/kg - additional doses at the discretion of the investigator based on FVIII activity level and clinical assessment of response to treatment (upper limit: 400 U/kg every 2 hours)
|
||||||||||||||||||
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Overall trial
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Overall trial | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis sets
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set title |
Intent to Treat Population
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set type |
Intention-to-treat | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set description |
Comprises subjects with initial serious bleeding episodes who were dosed and fro whom any post-screening data are available.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set title |
Pharmacokinetic Population
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set type |
Modified intention-to-treat | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set description |
Consists of all subjects in the ITT population with available PK data
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set title |
Safety Population
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set type |
Safety analysis | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set description |
Comprises all subjects who received one or more doses of investigational product.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
Treatment of serious bleeding episodes
|
||
Reporting group description |
Initial treatment with OBI-1 at dose of 200 U/kg, additional doses at the discretion of the investigator based on FVIII activity level and clinical assessment of response to treatment (upper limit: 400 U/kg every 2 hours) | ||
Subject analysis set title |
Intent to Treat Population
|
||
Subject analysis set type |
Intention-to-treat | ||
Subject analysis set description |
Comprises subjects with initial serious bleeding episodes who were dosed and fro whom any post-screening data are available.
|
||
Subject analysis set title |
Pharmacokinetic Population
|
||
Subject analysis set type |
Modified intention-to-treat | ||
Subject analysis set description |
Consists of all subjects in the ITT population with available PK data
|
||
Subject analysis set title |
Safety Population
|
||
Subject analysis set type |
Safety analysis | ||
Subject analysis set description |
Comprises all subjects who received one or more doses of investigational product.
|
|
|||||||||||||
End point title |
Percentage of Serious Bleeding Episodes Responsive to OBI-1 | ||||||||||||
End point description |
The initial serious ("qualifying") bleeding episode for each subject was analyzed for the primary efficacy outcome measure. A 'positive response' is defined as 'effective' (bleeding stopped with clinical control and FVIII levels of 50% or higher ) or 'partially effective' (bleeding reduced with clinical stabilization and FVIII levels of 20% or higher) control of bleeding, as determined by the investigator using a 4-point rating scale (effective - partially effective - poorly effective - not effective). 'Poorly effective' is defined as 'bleeding slightly reduced or unchanged and FVIII levels of less than 50%'. 'Not effective' is defined as 'bleeding worsening and FVIII levels of less than 50%'.
|
||||||||||||
End point type |
Primary
|
||||||||||||
End point timeframe |
24 hours after initiation of treatment
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Statistical significance | ||||||||||||
Statistical analysis description |
Summary statistics for the percentage of participants with serious bleeding episodes responsive at 24 hours after the initiation of treatment are presented, along with the 95% confidence interval (two-sided 95% Clopper-Pearson confidence interval).
|
||||||||||||
Comparison groups |
Treatment of serious bleeding episodes v Intent to Treat Population
|
||||||||||||
Number of subjects included in analysis |
58
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
other | ||||||||||||
P-value |
< 0.001 [1] | ||||||||||||
Method |
one-sided binomial exact test | ||||||||||||
Confidence interval |
|||||||||||||
Notes [1] - The p-value was determined from an exact approach because of the relatively small sample size. |
|
|||||||||||||
End point title |
Overall Percentage of Serious Bleeding Episodes Successfully Controlled With OBI-1 Therapy, as Assessed by the Investigator | ||||||||||||
End point description |
Treatment success was defined as control of qualifying bleeding episode at the time of final treatment dosing. A serious bleeding episode was considered 'successfully controlled' if the investigator had checked 'completed OBI-1 therapy as treatment success' on the eCRF.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
At the time of final treatment dosing (varied from participant to participant depending on bleeding episodes)
|
||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Percentage of Serious Bleeding Episodes Responsive to OBI-1 Therapy at 8 Hours After the Initiation of Therapy, as Assessed by the Investigator | ||||||||||||
End point description |
A 'positive response' is defined as 'effective' (bleeding stopped with clinical control and FVIII levels of 50% or higher ) or 'partially effective' (bleeding reduced with clinical stabilization and FVIII levels of 20% or higher) control of bleeding, as determined by the investigator using a 4-point rating scale (effective - partially effective - poorly effective - not effective). 'Poorly effective' is defined as 'bleeding slightly reduced or unchanged and FVIII levels of less than 50%'. 'Not effective' is defined as 'bleeding worsening and FVIII levels of less than 50%'. Please note that 21 subjects of the ITT population (n=29) had responses available at 8 hours after initial infusion of OBI-1.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
8 hours after initiation of therapy
|
||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Percentage of Serious Bleeding Episodes Responsive to OBI-1 Therapy at 16 Hours After the Initiation of Therapy, as Assessed by the Investigator | ||||||||||||
End point description |
A 'positive response' is defined as 'effective' (bleeding stopped with clinical control and FVIII levels of 50% or higher ) or 'partially effective' (bleeding reduced with clinical stabilization and FVIII levels of 20% or higher) control of bleeding, as determined by the investigator using a 4-point rating scale (effective - partially effective - poorly effective - not effective). 'Poorly effective' is defined as 'bleeding slightly reduced or unchanged and FVIII levels of less than 50%'. 'Not effective' is defined as 'bleeding worsening and FVIII levels of less than 50%'. Please note that 19 subjects of the ITT population (n=29) had responses available at 16 hours after initial infusion of OBI-1.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
16 hours after initiation of therapy
|
||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Frequency of Infusions of OBI-1 Required to Successfully Control Qualifying Bleeding Episodes | ||||||||||||
End point description |
'Frequency of infusions' was calculated as the 'average number of infusions per day'. 'Qualifying bleeding episode' was defined as the 'initial, serious bleeding episode'. The analysis was performed in 25 of 29 participants in the ITT population whose 'qualifying' bleeding episode was controlled successfully.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Time of successful control of qualifying bleeding episode (varied from subject to subject)
|
||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Total Dose of OBI-1 Required to Successfully Control 'Qualifying' Bleeding Episodes | ||||||||||||
End point description |
'Qualifying bleeding episode' was defined as the 'initial, serious bleeding episode'.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Time of successful control of qualifying bleeding episode (varied from subject to subject)
|
||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Total Number of Infusions of OBI-1 Required to Successfully Control 'Qualifying' Bleeding Episodes | ||||||||||||
End point description |
'Qualifying bleeding episode' was defined as the 'initial, serious bleeding episode'. A serious bleeding episode was considered 'successfully controlled' if the investigator had checked 'completed OBI-1 therapy as treatment success' on the eCRF.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Time of successful control of qualifying bleeding episode (varied from subject to subject)
|
||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
||||||||||||||||
End point title |
Correlation Between Response to OBI-1 Therapy at 8 Hours and Eventual Control of Serious Bleeding Episodes | |||||||||||||||
End point description |
It was assessed how many of the subjects who had a positive response at 8 hours after initial infusion of OBI-1 had their qualifying bleeding event eventually controlled. Of 21 subjects in the ITT population (n=29) with responses available at 8 hours after initial infusion of OBI-1, 20 had a positive response.
|
|||||||||||||||
End point type |
Secondary
|
|||||||||||||||
End point timeframe |
Time of successful control of qualifying bleeding episode (varied from subject to subject)
|
|||||||||||||||
|
||||||||||||||||
No statistical analyses for this end point |
|
||||||||||||||||
End point title |
Correlation Between Response to OBI-1 Therapy at 16 Hours and Eventual Control of Serious Bleeding Episodes | |||||||||||||||
End point description |
It was assessed how many of the subjects who had a positive response at 16 hours after initial infusion of OBI-1 had their qualifying bleeding event eventually controlled. All 19 subjects in the ITT population (n=29) with responses available at 16 hours after initial infusion of OBI-1 had a positive response.
|
|||||||||||||||
End point type |
Secondary
|
|||||||||||||||
End point timeframe |
Time of successful control of qualifying bleeding episode (varied from subject to subject)
|
|||||||||||||||
|
||||||||||||||||
No statistical analyses for this end point |
|
||||||||||||||||
End point title |
Correlation Between Response to OBI-1 Therapy at 24 Hours and Eventual Control of Serious Bleeding Episodes | |||||||||||||||
End point description |
It was assessed how many of the subjects who had a positive response at 24 hours after initial infusion of OBI-1 had their qualifying bleeding event eventually controlled. Of 29 subjects in the ITT population (n=29) with responses available at 24 hours after initial infusion of OBI-1, 25 had a positive response.
|
|||||||||||||||
End point type |
Secondary
|
|||||||||||||||
End point timeframe |
Time of successful control of qualifying bleeding episode (varied from subject to subject)
|
|||||||||||||||
|
||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Pharmacokinetic (PK) Analysis: Plasma clearance | ||||||||||||
End point description |
Participation in the PK sampling was optional. PK parameters obtained from the non-bleeding state were summarized with descriptive statistics.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Pre-infusion: 15-20 minutes, Post-infusion: 1, 3, 6, 12, 18, 24 hours
|
||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
PK Analysis: Volume of distribution at steady state | ||||||||||||
End point description |
Participation in the PK sampling was optional. PK parameters obtained from the non-bleeding state were summarized with descriptive statistics.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Pre-infusion: 15-20 minutes, Post-infusion: 1, 3, 6, 12, 18, 24 hours
|
||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
PK Analysis: Area Under the concentration-time curve (AUC) from time 0 to the last measurable concentration | ||||||||||||
End point description |
Participation in the PK sampling was optional. PK parameters obtained from the non-bleeding state were summarized with descriptive statistics. AUC was calculated as area under the percent activity-time curve.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Pre-infusion: 15-20 minutes, Post-infusion: 1, 3, 6, 12, 18, 24 hours
|
||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
PK Analysis: Terminal half-life | ||||||||||||
End point description |
Participation in the PK sampling was optional. PK parameters obtained from the non-bleeding state were summarized with descriptive statistics. Half-life was calculated as the time it took to reduce percent activity by half.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Pre-infusion: 15-20 minutes, Post-infusion: 1, 3, 6, 12, 18, 24 hours
|
||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
||||||||||
End point title |
Number of subjects who developed de novo anti-OBI-1 antibody titers | |||||||||
End point description |
Of 28 eligible subjects with acquired hemophilia A and autoimmune inhibitors to hFVIII in the ITT population (n=29), 18 had no detectable anti-porcine FVIII inhibitor titers at baseline (<0.6 BU) and 10 had detectable anti-porcine FVIII antibody titers at baseline (>=0.6 BU).
|
|||||||||
End point type |
Secondary
|
|||||||||
End point timeframe |
Through 90 days ± 7 days following final OBI-1 dose
|
|||||||||
|
||||||||||
No statistical analyses for this end point |
|
||||||||||
End point title |
Number of subjects who developed an anti-host cell protein baby hamster kidney (BHK) antibody titer | |||||||||
End point description |
21 subjects in the ITT population (n=29) had baseline and follow-up test results available.
|
|||||||||
End point type |
Secondary
|
|||||||||
End point timeframe |
Through 90 days ± 7 days following final OBI-1 dose
|
|||||||||
|
||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse events information
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
Through 90 days ± 7 days following final OBI-1 dose
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assessment type |
Non-systematic | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary used for adverse event reporting
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary name |
MedDRA | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary version |
13.1
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Safety Analysis Population
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Comprises all subjects who received one or more doses of investigational product (OBI-1). | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 5% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? Yes | |||
Date |
Amendment |
||
14 Jul 2010 |
- PK analyses modified to indicate that PK would be performed in both the non-bleeding and bleeding states (However, PK in bleeding state eventually not performed due to lack of acceptable data)
- Clarification made why serious subsequent bleeds would not be considered new qualifying bleeds
- Subjects who have received bypassing agents (eg, rFVIIa) or blood products would not be automatically excluded
- New maximum target blood level of FVIII for OBI-1 provided
- Inclusion and exclusion criteria were modified to clarify the required life expectancy before the qualifying bleeding event, the limit for prothrombin time (PT), and the required wash-out period for previous bypass therapy |
||
25 Jan 2011 |
- Schedule of assessments was modified beyond the 24-hour primary efficacy assessment to be less demanding for subjects who do not require frequent dosing, without changing the primary endpoint
- In response to an IRB request, language was added to specify that investigators are not required to collect information from pregnant subjects after study end but are required to provide counseling regarding risks to all pregnant subjects |
||
12 Feb 2012 |
The following changes were made based on comments received from health authorities in the United Kingdom, India
and from the Voluntary Harmonized Procedure countries (France, Germany, Italy, Hungary and Sweden) during their assessment of the clinical trial application:
- Changes were made to indicate that no subject could be included in the primary endpoint analysis for more than one bleeding event and that all subsequent bleeding events after the initial qualifying bleed would only be included in the safety
analysis.
- Inclusion criteria were added to indicate that subjects of reproductive age must use acceptable methods of contraception and if female, undergo pregnancy testing as part of the screening process.
- The scale used for the primary endpoint was changed from a three-point to a four-point ordinal scale with the inclusion of the assessment of “poorly controlled” bleeding.
- The minimum number of subjects to be included in the study was changed from 20 to 28.
The following additional change was made in response to a request from the DSMB:
- Assessment of complete blood count (CBC) with platelets was added to the schedule of assessments. |
||
13 May 2012 |
The wording of one inclusion criterion and two exclusion criteria was changed slightly in response to comments received from the French central ethics committee. |
||
03 Jul 2012 |
Wording of one inclusion criterion changed to allow for inclusion of a subject if consent is given by the subject, a trusted person or a person who is legally authorized to sign on behalf of the subject |
||
17 Apr 2013 |
The sponsor was changed from Inspiration Biopharmaceuticals, Inc. to Baxter. |
||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
Due to the low number of subjects available for evaluation, statistical tests could only be performed for the primary outcome measure. The results of all other outcome measures are descriptive. |